Faculty of Physical Therapy ,Cairo University
Giza, Egypt
Location contact
Rana Essam El Din Abd Elbar, Assistant lecturer
CONTACT
Rana Essam El Din Abd Elbar, assistant lect P.T
CONTACT
NCT Number: NCT07648524
This study aims to investigate the effect of cardiopulmonary rehabilitation on cardiorespiratory parameters and functional capacity in patients with pulmonary hypertension.
Trial opening soon.
Get Notified45 year–65 year
All sexes
Interventional
Not applicable
Giza, Egypt
Rana Essam El Din Abd Elbar, Assistant lecturer
CONTACT
Rana Essam El Din Abd Elbar, assistant lect P.T
CONTACT
Pulmonary hypertension is a progressive disease associated with reduced exercise capacity, respiratory muscle weakness, and impaired quality of life. Exercise training and respiratory muscle training have been shown to improve physical performance and quality of life in patients with pulmonary hypertension.
forty-two medically stable patients with Group III pulmonary hypertension due to lung diseases (obstructive and restrictive) will participate in this comparative experimental study. Participants will receive cardiopulmonary rehabilitation consisting of moderate-intensity interval aerobic training and inspiratory muscle training in addition to routine medical treatment. Outcome measures will include echocardiographic parameters, pulmonary function, six-minute walk distance, estimated VO2max, dyspnea severity, and quality of life. The study aims to evaluate the influence of cardiopulmonary rehabilitation on cardiorespiratory adaptation in patients with pulmonary hypertension.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
c)Forty two male patients with group 3 pulmonary hypertension (Chest cause) include Obstructive lung disease ( COPD and sleep apnea ) and restrictive lung disease (ILD). d)The patients' ages will range from 45 to 65 years old. e)BMI (25 - 34.9) kg/m2. f)World Health Organization (WHO) classification of functional classes II to III ( class II are patients with pulmonary hypertension who have a mild limitation of physical activity )(class III are patients with pulmonary hypertension who have a marked limitation of physical activity
Exclusion criteria
l)Impaired vision and/or hearing.
m)Patients who are unable to follow verbal instructions. n)acute exacerbation condition. o)unstable angina, serious cardiac dysrhythmias on resting ECG.
Training will be conducted on a treadmill three times weekly for 12 weeks. Exercise intensity will progress from 30-40% to 60-70% of target heart rate. Each session will last 30 minutes and include warm-up and cool-down periods.
inspiratory muscle training will be performed using a Threshold Inspiratory Muscle Trainer (Philips Respironics). Training intensity will correspond to moderate-to-severe effort (3-5 on the Modified Borg Scale).
medication
Time frame: 12 weeks
total distance walked in 6 minutes
Time frame: 12weeks
Estimated VO2max
Time frame: 12weeks
FEV1, FVC, FEV1/FVC, MVV
Time frame: 12weeks
Modified Borg Scale
Time frame: 12weeks
pulmonary artery pressure estimated by ECHO
Time frame: 12weeks
more increase scores more increase quality of life
Contact information is provided by the study sponsor or research team.
Cairo University
Other
Influence of Cardiopulmonary Rehabilitation on Cardiorespiratory Adaptation in Patients With Pulmonary Hypertension: A Comparative Experimental Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07285655
Cardiovascular Diseases, Hypertension
Scottsdale, Arizona, United States
View Trial Details